Basic Information | Post buying leads | Suppliers |
Name |
Nelarabine |
EINECS | N/A |
CAS No. | Density | N/A | |
PSA | N/A | LogP | N/A |
Solubility | N/A | Melting Point |
N/A |
Formula | N/A | Boiling Point | N/A |
Molecular Weight | N/A | Flash Point | N/A |
Transport Information | N/A | Appearance | N/A |
Safety | Risk Codes | N/A | |
Molecular Structure | Hazard Symbols | N/A | |
Synonyms |
N/A |
Empirical Formula: C11H15N5O5
Molecular Weight: 297.2673 g/mol
Index of Refraction: 1.829
Density: 1.98 g/cm3
Flash Point: 389.9 °C
Enthalpy of Vaporization: 110.58 kJ/mol
Boiling Point: 721 °C at 760 mmHg
Vapour Pressure: 8.06E-22 mmHg at 25 °C
Structure of Nelarabine (CAS NO.121032-29-2):
Nelarabine (CAS NO.121032-29-2) is used as a chemotherapy drug in T-cell acute lymphoblastic leukemia.
Nelarabine , its cas register number is 121032-29-2. It also can be called (2R,3S,4R,5R)-2-(2-amino-6-methoxy-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol ; Arranon ; and TAtriance . It was previously known as 506U78, and is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity. In October 2005, Nelarabine (CAS NO.121032-29-2) was approved by the FDA for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least two chemotherapy regimens. It was later approved in the European Union on August 22, 2007.